Repare Therapeutics Q2 EPS $(0.82) Beats $(0.87) Estimate, Sales $1.07M Miss $2.92M Estimate
Portfolio Pulse from Benzinga Newsdesk
Repare Therapeutics (NASDAQ:RPTX) reported Q2 EPS of $(0.82), beating the $(0.87) estimate, but missed sales estimates with $1.07M against $2.92M expected. EPS improved from last year, but sales significantly declined.
August 06, 2024 | 8:46 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Repare Therapeutics reported a Q2 EPS of $(0.82), beating the $(0.87) estimate, but missed sales estimates with $1.07M against $2.92M expected. EPS improved from last year, but sales significantly declined.
While the EPS beat expectations, the significant miss on sales and the drastic year-over-year decline in revenue could create mixed reactions in the market. Investors may be concerned about the company's revenue generation capabilities despite the improved EPS.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100